Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention - Results from The Clopidogrel for the Reduction of Events During Observation (CREDO) trial
Article
Beinart, SC, Kolm, P, Veledar, E et al. (2005). Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention - Results from The Clopidogrel for the Reduction of Events During Observation (CREDO) trial
. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 46(5), 761-769. 10.1016/j.jacc.2005.03.073
Beinart, SC, Kolm, P, Veledar, E et al. (2005). Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention - Results from The Clopidogrel for the Reduction of Events During Observation (CREDO) trial
. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 46(5), 761-769. 10.1016/j.jacc.2005.03.073
Open AccessIndustry CollaborationInternational Collaboration